Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon

Lily Liu, Liuzhe Li, Aubin Nanfack, Luzia M. Mayr, Sonal Soni, Adam Kohutnicki, Lucy Agyingi, Xiao Hong Wang, Michael Tuen, Yongzhao Shao, Maxim Totrov, Susan Zolla-Pazner, Xian Peng Kong, Ralf Duerr, Miroslaw K. Gorny

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


The results of the RV144 vaccine clinical trial showed a correlation between high level of anti-V1V2 antibodies (Abs) and a decreased risk of acquiring HIV-1 infection. This turned the focus of HIV vaccine design to the induction of elevated levels of anti-V2 Abs to increase vaccine efficacy. In plasma samples from HIV-1 infected Cameroonian individuals, we observed broad variations in levels of anti-V2 Abs, and 6 of the 79 plasma samples tested longitudinally displayed substantial deficiency of V2 Abs. Sequence analysis of the V2 region from plasma viruses and multivariate analyses of V2 characteristics showed a significant difference in several features between V2-deficient and V2-reactive plasma Abs. These results suggest that HIV vaccine immunogens containing a shorter V2 region with fewer glycosylation sites and higher electrostatic charges can be beneficial for induction of a higher level of anti-V2 Abs and thus contribute to HIV vaccine efficacy.

Original languageEnglish
Pages (from-to)57-64
Number of pages8
StatePublished - Mar 2019


  • HIV-1
  • V1V2 region
  • V2 antibody deficiency
  • V2 conformational antibodies
  • V2 linear antibodies


Dive into the research topics of 'Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon'. Together they form a unique fingerprint.

Cite this